Daniel Clark Analyst PerformanceVice President - Equity Research at Leerink PartnersDaniel Clark is a stock analyst at Leerink Partners in the healthcare sector, covering 10 publicly traded companies. Over the past year, Daniel Clark has issued 16 stock ratings, including buy and hold recommendations. While full access to Daniel Clark's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Daniel Clark's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings19 Last 1 YearsBuy Recommendations83.33% 15 Buy RatingsCompanies Covered10 Unique Companies Ratings Distribution18RatingsDistribution of strong buy, buy, hold, and sell ratings by Daniel Clark.RatingPercentageCount Strong Buy0.0%0 ratings Buy83.3%15 ratings Hold16.7%3 ratings Sell0.0%0 ratingsOut of 18 total stock ratings issued by Daniel Clark at Leerink Partners, the majority (83.3%) have been Buy recommendations, followed by 16.7% Hold.Best & Worst CallsBest Call000.0%ELANJul 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call00.0%IDXXJun 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ70.0% of companies on NASDAQ7 companiesNYSE30.0% of companies on NYSE3 companiesDaniel Clark, an analyst at Leerink Partners, currently covers 10 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare10 companies100.0%Daniel Clark of Leerink Partners specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentagePHARMACEUTICALS8 companies80.0%HEALTHCARE EQUIPMENT & SUPPLIES2 companies20.0% Daniel Clark's Ratings History at Leerink Partners Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsBLCOBausch + Lomb9/9/2026Initiated Coverage$17.77$24.00Outperform$0.0000.00% ROICOLLCollegium Pharmaceutical9/9/2026Initiated Coverage$23.37$45.00Outperform$0.0000.00% ROIAMRXAmneal Pharmaceuticals9/9/2026Initiated Coverage$17.05$23.00Outperform$0.0000.00% ROIPHATPhathom Pharmaceuticals9/9/2026Initiated Coverage$9.43$10.00Market Perform$0.0000.00% ROIHROWHarrow9/9/2026Initiated Coverage$37.85$45.00Outperform$0.0000.00% ROIVTRSViatris9/9/2026Initiated Coverage$16.61$20.00Outperform$0.0000.00% ROIPCRXPacira BioSciences9/9/2026Initiated Coverage$25.36$28.00Market Perform$0.0000.00% ROITEVATeva Pharmaceutical Industries9/9/2026Initiated Coverage$37.12$45.00Outperform$0.0000.00% ROIAMRXAmneal Pharmaceuticals9/9/2026Initiated Coverage$17.25$23.00Outperform$0.0000.00% ROIBLCOBausch + Lomb9/9/2026Initiated Coverage$17.82$24.00Outperform$0.0000.00% ROIHROWHarrow9/9/2026Initiated Coverage$37.55$45.00Outperform$0.0000.00% ROIPHATPhathom Pharmaceuticals9/9/2026Initiated Coverage$8.67$10.00Hold$0.0000.00% ROIVTRSViatris9/9/2026Initiated Coverage$16.50$20.00Outperform$0.0000.00% ROICOLLCollegium Pharmaceutical9/9/2026Initiated Coverage$23.37$45.00Outperform$0.0000.00% ROIELANElanco Animal Health2/24/2026Boost Price Target$25.77$30.00Outperform$0.0000.00% ROIIDXXIDEXX Laboratories11/3/2025Set Price Target$722.94$785.00$0.0000.00% ROIELANElanco Animal Health7/17/2025Upgrade$14.51$18.00Outperform$00.0000.00% ROIIDXXIDEXX Laboratories7/17/2025Boost Price Target$519.61$600.00Outperform$000.0000.00% ROIIDXXIDEXX Laboratories6/11/2025Boost Price Target$522.26$580.00Outperform$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
